Research and Markets: OTC Opportunities in Europe, the US and Japan: Key Trends, Leading Players and Future Rx-OTC Switching

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/192d65/otc_opportunities) has
announced the addition of the "OTC Opportunities in Europe, the US and Japan:
Key Trends, Leading Players and Future Rx-OTC Switching" report to their
offering.

The developed OTC markets such as the US and UK are heavily reliant on Rx-to-OTC
switching of new generation products as a means of generating growth. Switching
also plays an important role for less-developed markets (e.g. France, Spain,
Italy, Japan), though in this case they are playing catch-up with the more
developed markets. The Power of Switch was brought into sharp focus in 2009 with
the first ever use of the Centralized Procedure for switching products
throughout the European Union. This comprehensive report provides background on
market dynamics (including overall market size and therapeutic category size)
for each of the core countries under analysis.

This report also examines products and categories that are likely to be switched
in the future, regulatory changes that are likely to impact the OTC market, and
provides growth forecasts to 2013. Included in the report are case studies for
two of the most significant switches of recent years i.e. Alli (orlistat) and
Zocor (simvastatin).

Key features of this report

* Comprehensive examination of recent trends and developments in the featured
countries.
* Market sizes and category sizes in 7 core markets.
* Case studies of the switches of orlistat and statins.
* Examination of regulatory changes that are likely to impact upon OTC markets
in the future

Scope of this report

* Provides a clear and concise understanding of the dynamics of the global OTC
market.
* Demonstrates how the dynamics of the OTC markets in the various countries
differ widely, but also how they relate to each other.
* Identifies and examines examples of successful switches, which can be used as
a model for future switches.
* Highlights switches that failed and examines possible causes for failure.
* Allows marketers to plan ahead: Anticipating what switches are likely to take
place in future; and take into account other regulatory changes that are likely
to take place.

Key Market Issues

* In 2008, the global pharmaceutical market grew by 4.8% to reach $773bn (MSP),
while the global OTC market grew by 7.6% to reach $79.3bn (MSP). Although OTC
growth in recent years has been driven by emerging markets such as China and
Eastern Europe, the developed markets of North America, Western Europe and the
Pacific Rim together account for over 50% of global OTC turnover.
* Although most Rx-to-OTC switches are driven by manufacturers; governments
around the world increasingly view Rx-to-OTC switching as a means of relieving
pressure on overburdened health insurance systems.
* Throughout the world, access to OTCs is increasing. In some countries, the
increased access is derived mainly from pioneering switches from Rx-to-OTC;
while, in others, the increased access is derived mainly from the opening up of
distribution channels and from an easing of advertising restrictions.

Key findings from this report

* In all seven featured countries, OTC market expansion is being fuelled by
Rx-to-OTC switching.
* The success of new-generation switches often relies on a collaborative care
model, involving co-operation between consumers, doctors and pharmacists.
* In the future, the collaborative care model could potentially be used as a
basis for switching products for treating conditions such as asthma,
hypertension, hyperglycemia and osteoporosis. There is also scope for switching
products for treating conditions for which the timing of treatment is critical:
for example, adrenaline injectors containing epinephrine and antivirals such as
Roches Tamiflu (oseltamivir).

Key questions answered

* What opinion do various stakeholders (i.e. consumers, regulators,
manufacturers, healthcare professionals) have on Rx-to-OTC switches?
* What does the future hold for the global OTC market?
* What Rx-to-OTC switches might there be in the future?

Key Topics Covered:

* OTC opportunities in Europe, the US and Japan
* Chapter 1 Introduction
* Chapter 2 OTC trends and opportunities in
* Chapter 3 OTC trends and opportunities in the US
* Chapter 4 OTC trends and opportunities in
* Chapter 5 Case studies of switches of orlistat and statins
* Chapter 6 Conclusions and forecasts
* Chapter 7 Appendix
* List of Figures
* List of Tables

For more information visit
http://www.researchandmarkets.com/research/192d65/otc_opportunities

Source: Business Insights

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2010